Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Primary care

Lupus often presents with a butterfly rash.

Top 12: Research in Systemic Lupus Erythematosus at a Glance

David S. Pisetsky, MD, PhD  |  November 18, 2021

Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.

Filed under:ACR ConvergenceConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLE

Howard Blumstein, MD, Assumes RheumPAC Chair

RenĂ©e Bacher  |  November 18, 2021

“Advocacy is not about bribery. There’s nothing dirty about advocating for your patients and the future of your profession in terms of workforce, therapeutic advances and the financial viability of our practices. It’s our duty to do this,” he says. In his new role as the RheumPAC chair, he wants to help ACR/ARP members “see how vital these activities are to the success of our profession.”

Filed under:Legislation & AdvocacyProfiles Tagged with:AdvocacyHoward BlumsteinRheumPACVolunteering

New Video Shows How to Perform a Lip Biopsy to Diagnose Sjögren’s Syndrome

Susan Bernstein  |  November 14, 2021

Labial salivary gland biopsy (i.e., lip biopsy) is a useful tool to help diagnose Sjögren’s syndrome in suspected patients, but most rheumatologists are not trained to perform the minimally invasive procedure. A new, 40-minute training video and slide presentation with step-by-step instructions may help them fill that critical skill gap. Two rheumatologists collaborated to create…

Filed under:ConditionsOther Rheumatic ConditionsSjögren’s Disease Tagged with:biopsySjogren's

2 ARP Volunteers Share Their Enriching Experiences

Elizabeth Hofheinz, MPH, MEd  |  November 14, 2021

It may not take a village, but when it comes to providing stellar care to rheumatology and musculoskeletal patients, it definitely takes a team. To ensure all rheumatology professionals are thoroughly prepared to serve their patients’ needs in a personalized manner, there is the ARP—the Association of Rheumatology Professionals. The ARP, the interprofessional division of…

Filed under:Interprofessional Perspective Tagged with:interdisciplinaryVolunteerism

A Dematologist’s Perspective on Choosing an Anti-Psoriatic Drug

Samantha C. Shapiro, MD  |  October 15, 2021

We are fortunate to have clinical practice guidelines for the management of psoriasis and psoriatic arthritis (PsA) from multiple organizations to help navigate today’s rapidly evolving therapeutic landscape. We are further fortunate to have multiple specialists to manage these conditions: rheumatologists and dermatologists. However, multiple guidelines, multiple drugs and multiple specialists can create a paradox…

Filed under:Biologics/DMARDsConditionsPsoriatic Arthritis Tagged with:Psoriatic Arthritis

Fall 2021’s Awards, Appointments & Announcements in Rheumatology

Gretchen Henkel  |  October 13, 2021

Jeffrey Siegel, MD, Assumes New Position as Director for New Office of Drug Evaluation Sciences at the FDA On Feb. 16, Jeffrey Siegel, MD, became the director of the recently created Office of Drug Evaluation Sciences at the U.S. Food & Drug Administration (FDA). The move, he says, “puts together many of the different things…

Filed under:Awards Tagged with:Dr. Carol ZiminskiDr. Gordon HutchinsonDr. Jason SpringerDr. Jeffrey SiegelDr. Sebastian Sattui

Regressed germinal center with follicular dendritic cell prominence (star), onion-skinning (blue arrowhead) and increased vascularity (orange arrows) are seen.

Case Report: Is It Castleman Disease, or Castleman-Like?

Philip Chu, MD, RhMSUS, Mithu Maheswaranathan, MD, Jadee L. Neff, MD, PhD, & Rebecca E. Sadun, MD, PhD  |  October 13, 2021

The difference between Castle­man disease and Castleman-like disease may be subtle, but it comes with significant ramifications. Case Presentation This case involves a pregnant 19-year-old woman who presents over multiple hospitalizations with concerns for systemic lupus erythematosus and macrophage activation syndrome. At 36 weeks’ gestation, the patient’s weight had dropped from 215 lbs. to 170…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:case reportCastleman's disease

The Dual-Target Strategy in Rheumatoid Arthritis: Put Patients First

Ricardo J.O. Ferreira, RN, PhD; Leonard H. Calabrese, DO; & JosĂ© A.P. Da Silva, MD, PhD  |  October 13, 2021

The impressive progress of medical knowledge and technology reinforces our trust in the scientific methodology that made it all possible. However, that progress also creates risks related to the primary goal of medical care: to serve our patients’ interests and enjoyment of life in the best possible way. In this article we present our views…

Filed under:ConditionsPatient PerspectiveRheumatoid ArthritisSpeak Out Rheum Tagged with:Disease Activity Score (DAS)patient centerednessshared decision makingSpeak Out RheumatologyTreat-to-Target

The Latest Psoriatic Arthritis Management Insights

Jason Liebowitz, MD, FACR  |  October 11, 2021

An overview of the research to date and the ways in which such evidence can be used to guide the treatment of patients was presented at the 2019 ACR/ARP Annual Meeting in a session titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater…

Filed under:ConditionsPsoriatic Arthritis Tagged with:Psoriatic Arthritis

FDA Approves Avacopan for the Treatment of ANCA-Associated Vasculitis

ChemoCentryx  |  October 8, 2021

On Oct. 8, ChemoCentryx Inc. announced that the U.S. Food & Drug Administration (FDA) has approved avacopan (TAVNEOS), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms…

Filed under:Biologics/DMARDsConditionsDrug UpdatesVasculitis Tagged with:avacopan

  • « Previous Page
  • 1
  • …
  • 78
  • 79
  • 80
  • 81
  • 82
  • …
  • 137
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences